Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.43 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | IL18 | Q14116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13770863 | 0.86 | MAPT (0.42) | EPHX1MAPTLMNAMEN1KMT2A | |
| SCHEMBL8953567 | 0.78 | GSK3B (0.51) | PAX8KDM4ERAB9AEPHX2NPC1 | |
| SCHEMBL9819214 | 0.78 | GSK3B (0.51) | MAPTLMNATSHRHTTNLRP3 | |
| SCHEMBL7180799 | 0.74 | IDO1 (0.40) | LMNATSHRHTTPOLBMAPK1 | |
| SCHEMBL20941781 | 0.73 | MAPT (0.56) | EPHX1MAPTLMNATSHRHTT | |
| SCHEMBL9638528 | 0.73 | — | — | |
| SCHEMBL9819207 | 0.72 | GSK3B (0.49) | MAPTLMNATSHRHTTNLRP3 | |
| SCHEMBL9204753 | 0.72 | CHRNB2 (0.44) | MAPTMEN1KMT2AKDM4E | |
| SCHEMBL20941550 | 0.72 | MAPT (0.54) | MAPTLMNATSHRHTTNLRP3 | |
| SCHEMBL20941782 | 0.72 | MAPT (0.54) | EPHX1MAPTLMNATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2685983-B1 | NOVEL USE OF IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-05-18 | — | — | EP | claimed |
| US-20140057978-A1 | NOVEL USE OF BENZOFURANYLSULFONATES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2014-02-27 | — | — | US | claimed |
| US-20140038967-A1 | NOVEL USE FOR IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2014-02-06 | — | — | US | claimed |
| EP-2685983-A1 | NOVEL USE OF IMIDAZOTRIAZINONES | Algiax Pharmaceuticals GmbH (DE) | 2014-01-22 | — | — | EP | claimed |
| EP-2685975-A1 | NOVEL USE OF BENZOFURANYLSULFONATES | Algiax Pharmaceuticals GmbH (DE) | 2014-01-22 | — | — | EP | claimed |
| US-20130274301-A1 | Novel Use of Leflunomide and Malononitrilamides | AL-GIAX PHARMACEUTICALS GMBH (DE) | 2013-10-17 | — | — | US | claimed |
| EP-2608782-A1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | Algiax Pharmaceuticals GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012123353-A1 | NOVEL USE OF BENZOFURANYLSULFONATES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-09-20 | — | — | WO | claimed |
| WO-2012123406-A1 | NOVEL USE OF IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-09-20 | — | — | WO | claimed |
| WO-2012025217-A1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-0787491-B1 | PREVENTIVE AND REMEDY FOR TYPE I ALLERGIC DISEASES | AVENTIS PHARMA LTD (JP) | 2000-07-26 | — | — | EP | claimed |
| US-5814649-A | ALLERGIC DISEASES AND TREATMENT WITH AROMATIC AMIDES WITH IMMUNOGLOBULIN INHIBITORS | HOECHST PHARMACEUTICALS & CHEMICALS K.K. (JP) | 1998-09-29 | — | — | US | claimed |
| EP-0787491-A1 | PREVENTIVE AND REMEDY FOR TYPE I ALLERGIC DISEASES | HOECHST JAPAN LIMITED (JP) | 1997-08-06 | — | — | EP | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12409191-B2 | Renal cell populations and uses thereof | PROKIDNEY (KY) | 2025-09-09 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | SANKYO COMPANY, LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-0787491-B1 | PREVENTIVE AND REMEDY FOR TYPE I ALLERGIC DISEASES | AVENTIS PHARMA LTD (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0787491-A1 | PREVENTIVE AND REMEDY FOR TYPE I ALLERGIC DISEASES | HOECHST JAPAN LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | EPHX1 3262/4885PAX8 2523/4885MAPT 3890/4885 |
| US-20140038967-A1 | NOVEL USE FOR IMIDAZOTRIAZINONES | ATP6V1B2, INA, CAMK2B | EPHX1 2098/4885PAX8 2601/4885MAPT 496/4885 |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | PHOSPHO1, CD4, FCGRT | EPHX1 2839/4885PAX8 2528/4885MAPT 3715/4885 |
| US-20130274301-A1 | Novel Use of Leflunomide and Malononitrilamides | LEF1, TPMT, MALT1 | EPHX1 1130/4885PAX8 360/4885MAPT 2343/4885 |
| US-20140057978-A1 | NOVEL USE OF BENZOFURANYLSULFONATES | ATP6V1B2, PMP22, KIT | EPHX1 1338/4885PAX8 1061/4885MAPT 1142/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | EPHX1 3367/4885PAX8 2815/4885MAPT 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.